Takeda Pharmaceutical (TAK) Net Cash Flow Growth (3y) (2021 - 2026)
Takeda Pharmaceutical (TAK) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.21 Bn | 39.55 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.48 Bn | 29.80 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.49 Bn | 15.10 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | -22.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.55% |
| Mar 31, 2026 | 37.89% |
| Dec 31, 2025 | 24.24% |
| Sep 30, 2025 | 28.08% |
| Jun 30, 2025 | 49.46% |
| Mar 31, 2025 | -39.47% |
| Dec 31, 2024 | -66.65% |
| Sep 30, 2024 | 51.83% |
| Jun 30, 2024 | 39.89% |
| Mar 31, 2024 | -29.53% |
| Dec 31, 2023 | -22.84% |
| Sep 30, 2023 | -26.73% |
| Jun 30, 2023 | -57.89% |
| Mar 31, 2023 | -12.09% |
| Sep 30, 2022 | -26.90% |
| Jun 30, 2022 | -24.98% |
| Mar 31, 2022 | 44.56% |
| Dec 31, 2021 | 137.64% |
| Sep 30, 2021 | -37.80% |
| Jun 30, 2021 | -74.69% |